This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
Conditions: Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Eligibility Criteria
Inclusion Criteria
- Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.
- Candidacy to receive treatment with docetaxel.
- Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR
- ECOG performance status 0-2
Exclusion Criteria
- Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).
- Active brain metastases.
- Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study.
Eligibility criteria are kept as the original English records from ClinicalTrials.gov; actual eligibility is determined by the research team's formal assessment and the informed consent form. Source: ClinicalTrials.gov, updated automatically every two weeks. Last synced: 2026年10月8日.